EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Mesenchymal stem/stromal cell-based therapies for autism spectrum disorder: emerging evidence and clinical prospects

Minghui Xu iD, Xiaohan Zhang, Yuqian Liu, Yue Yang, Zijing Zhou, Jun Ma, Sanbing Shen

Journal of Translational Medicine · 20.03.2026 · 24 (1)

DOI: 10.1186/s12967-026-08030-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Translational Medicine, online erschienen am 20.03.2026. Verfasst von Minghui Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell Research Center, Hebei Medical University-Galway University, Hebei Medical University, Shijiazhuang, Hebei Province, 050017, China. xumingh…. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with rising global prevalence. Current management strategies predominantly address behavioral symptoms rather than core neurobiological dysfunctions, highlighting an unmet need for mechanism-targeted interventions. MAIN BODY: This review comprehensively evaluates the therapeutic potential of mesenchymal stem/stromal cell (MSC)-based therapies for ASD. We discuss the multi-faceted mechanisms through which MSCs and their secretomes (particularly MSC-EVs or MSC-exos) may ameliorate ASD pathophysiology, including modulation of neuroinflammation via anti-inflammatory cytokine and adenosine signaling, promotion of neurogenesis and synaptic plasticity through neurotrophic factors (e.g., BDNF, GDNF), restoration of gut-brain axis communication, and enhancement of cerebral angiogenesis via VEGF. We synthesize a decade of preclinical evidence (2015–2025) from various ASD animal models (e.g., BTBR, VPA-induced, MIA, Shank3B KO), detailing improvements in social behavior, repetitive actions, and cognitive function following MSC or MSC-derived product administration via routes such as intravenous, intranasal, or intracerebroventricular delivery. Furthermore, we analyze all registered early-phase clinical trials (Phase I and II, n = 9 as of March 2026), comparing different MSC sources, their safety profiles, and preliminary efficacy outcomes. Key challenges are examined, including heterogeneity in trial design, small sample sizes, the predominance of open-label studies, and the gap between promising preclinical results and established clinical translation. CONCLUSIONS: MSC-based therapy represents a transformative, pathophysiology-informed strategy for ASD. While preclinical and early clinical data are encouraging, significant hurdles remain in standardization, dose optimization, and demonstration of long-term efficacy and safety. We emphasize the necessity for rigorous, large-scale randomized controlled trials (RCTs) to advance this promising therapeutic approach toward clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autism Spectrum DisorderMesenchymal Stem Cell TransplantationMesenchymal Stem CellsHumansAnimalsClinical Trials as Topic

Stichwörter der Autor:innen

Autism spectrum disorderCell therapyClinical trialMesenchymal stem/stromal cellRegenerative medicineTranslational medicine

Autor:innen und Institutionen

  • Stem Cell Research Center, Hebei Medical University-Galway University, Hebei Medical University, Shijiazhuang, Hebei Province, 050017, China. xuminghui9809@163.com.
  • Hebei Research Center for Stem Cell Medical Translational Engineering, Shijiazhuang, Hebei Province, 050017, China. xuminghui9809@163.com.
  • Hebei Technology Innovation Center for Stem Cell and Regenerative Medicine, Shijiazhuang, Hebei Province, China. xuminghui9809@163.com.
  • Hebei International Joint Research Center for Stem Cell and Regenerative Medicine, Shijiazhuang, Hebei Province, China. xuminghui9809@163.com.
  • Stem Cell Research Center, Hebei Medical University-Galway University, Hebei Medical University, Shijiazhuang, Hebei Province, 050017, China.
  • Hebei Research Center for Stem Cell Medical Translational Engineering, Shijiazhuang, Hebei Province, 050017, China.

ORCID-Profile: Minghui Xu

Zitieren

APA

Xu, M., Zhang, X., Liu, Y., Yang, Y., Zhou, Z., Ma, J., & Shen, S. (2026). Mesenchymal stem/stromal cell-based therapies for autism spectrum disorder: emerging evidence and clinical prospects. Journal of Translational Medicine, 24(1). https://doi.org/10.1186/s12967-026-08030-3

Vancouver

Xu M, Zhang X, Liu Y, Yang Y, Zhou Z, Ma J, et al. Mesenchymal stem/stromal cell-based therapies for autism spectrum disorder: emerging evidence and clinical prospects. Journal of Translational Medicine. 2026;24(1). doi:10.1186/s12967-026-08030-3

BibTeX
@article{Xu2026,
  author = {Xu, Minghui and Zhang, Xiaohan and Liu, Yuqian and Yang, Yue and Zhou, Zijing and Ma, Jun and Shen, Sanbing},
  title = {Mesenchymal stem/stromal cell-based therapies for autism spectrum disorder: emerging evidence and clinical prospects},
  journal = {Journal of Translational Medicine},
  year = {2026},
  volume = {24},
  number = {1},
  doi = {10.1186/s12967-026-08030-3}
}
Kostenlos starten →